7ZT Share Price Performance
€0.46
0.09 (25.31%)
Price €0.46
Share Price€0.46
7ZT Community Narratives
There are no narratives available yet.
Recent 7ZT News & Updates
No updates
Hamlet BioPharma AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 28, 2025
- Earnings per share (EPS)
- -0.27
- Gross Margin
- 100.00%
- Net Profit Margin
- -27,346.83%
- Debt/Equity Ratio
- 0%
Hamlet BioPharma AB (publ) Competitors
About 7ZT
- Founded
- 1999
- Employees
- 7
- CEO
- WebsiteView website
Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company’s products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer. The company was formerly known as Hamlet Pharma AB (publ) and changed its name to Hamlet BioPharma AB (publ) in August 2023. Hamlet BioPharma AB (publ) was incorporated in 1999 and is based in Lund, Sweden. Hamlet BioPharma AB (publ) is a subsidiary of Linnane Pharma AB.
Swedish Market Performance
- 7 Days: -2.2%
- 3 Months: 3.1%
- 1 Year: 3.0%
- Year to Date: -0.9%
Over the last 7 days, the market has dropped 2.2%, driven by a loss of 2.5% in the Industrials sector. Although the market performance has been flat over the past year. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading